Nasdaq: $28.12 (-1.61) | AIM: £4.12 (-0.04)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China,  strive to create differentiated novel oncology and immunology treatments with global potential.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.